Duodopa (levodopa/carbidopa intraduodenal gel infusion) / AbbVie - LARVOL DELTA

Electrophysiological and biochemical evaluations of neuropathy risk in oral levodopa versus levodopa/carbidopa intestinal gel treatment. (PubMed, Arq Neuropsiquiatr) - "Correlation analyses indicated significant associations involving homocysteine elevation and conduction abnormalities.Patients receiving LCIG presented higher homocysteine levels and more frequent electrophysiological abnormalities than those on oral treatment, suggesting a higher risk of polyneuropathy. These findings highlight the importance of biochemical monitoring and individualized treatment strategies in advanced PD."

Clinical • Journal • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease

Loss of therapeutic efficacy following the switch from levodopa/carbidopa intestinal gel therapy to subcutaneous foslevodopa/foscarbidopa infusion in a patient with advanced Parkinson's disease. (PubMed, Neurol Neurochir Pol) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies. (PubMed, Mov Disord Clin Pract) - "While equally effective, CSFLI requires closer supervision during early management. Recognizing these practical differences can guide therapy selection and service planning in advanced PD."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Selection of patients with Parkinson's disease for interventional therapies: A review of available tools - scales and questionnaires (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "A systematic review of available PubMed publications was conducted to identify the criteria for selecting patients with PD for IT, including deep brain stimulation (DBS) and levodopa-carbidopa intestinal gel (LCIG), as well as to assess the available scales and tools that facilitate the timely referral of patients...Assessment scales help to develop more accurate and informed decisions, ultimately improving patients' treatment outcomes and quality of life. Further research is needed to improve these tools."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Cost-Effectiveness Analysis of Inhaled Levodopa for Managing OFF Episodes in Patients With Parkinson's Disease (ISPOR-EU 2025) - "After discontinuing treatment, patients received a basket of subsequent therapies including apomorphine, levodopa-carbidopa intestinal gel and deep brain stimulation. The base-case results demonstrate inhaled levodopa is associated with 6.648 quality-adjusted life years (QALY), and £153,378 total costs. The cost-effectiveness analysis results, alongside the NMB, indicate inhaled levodopa could be a cost-saving alternative in the management of OFF episodes in PD patients for the UK population."

Clinical • Cost effectiveness • HEOR • CNS Disorders • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease

The effect of 12-week Yoga intervention on motor symptoms, fear of falling, and quality of Life in Parkinson's disease with duodopa pump in patients age 50 - 80 years old. (ANZCTR) - P=N/A | N=10 | Completed | Sponsor: Academy of Physical Education in Katowice

HEOR • New trial • CNS Disorders • Movement Disorders • Otorhinolaryngology • Parkinson's Disease

Foslevodopa-foscarbidopa infusion. (PubMed, Pract Neurol) - "Deep brain stimulation, levodopa-carbidopa intestinal gel and subcutaneous apomorphine are established non-oral treatments for advanced Parkinson's disease but delivery of these therapies is restricted to small numbers in specialist centres. Here, we provide experience and practical insights from delivering a CSFFI service within the UK National Health Service. We highlight advantages of CSFFI vs alternative device-aided treatment options and outline a framework for starting and maintaining treatment, including managing common side effects, illustrated by patient cases."

Journal • CNS Disorders • Hepatology • Movement Disorders • Parkinson's Disease

When post-radiotherapy parkinsonism can hide another one : A case report. (MDS Congress 2025) - "The patient reached the stage of motor fluctuations 5 years later, with subsequent use of a Duodopa pump therapy... This case illustrates the need for long-term follow-up of cranial radiotherapy patients, and that initial regression of post-radiotherapy parkinsonism does not guarantee long-term outcome."

Case report • Clinical • CNS Disorders • Dystonia • Movement Disorders • Parkinson's Disease

Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis (MDS Congress 2025) - P | "These data suggest that LECIG treatment for up to one year is generally well tolerated by patients with advanced PD. As has been observed with levodopa–carbidopa intestinal gel infusion, the most frequent AEs are associated with the procedure or the device. Table 1"

Adverse events • CNS Disorders • Movement Disorders • Parkinson's Disease

Real-life experience with continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced stage of Parkinson's disease at Villa Margherita (MDS Congress 2025) - "Objective: We present the results of our case series with continuous subcutaneous infusion (CSCI) produodopa in 2024, focusing on tolerability and efficacy, in line with clinical trial findings. We confirm that in a real-life setting CSCI is a safe and efficacious treatment for patients with advanced PD."

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Nutrition, Motor And Non-Motor Symptoms Impact On Life's Quality In Parkinson's Disease In Second-Line Therapies (MDS Congress 2025) - "Our results revealed that a better nutritional status was associated with better motor and non-motor performance, impacting PD patients' QoL. The DBS group obtained better results than the LCIG group. In PD patients with second-line therapies, better nutritional status was associated with better performance on motor and non-motor symptoms, ultimately impacting QoL."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Deep Brain Stimulation in Late-Stage Parkinson's Disease: Insights from Clinical Practice (MDS Congress 2025) - " Twenty-five patients were included: 15 continued with medical therapy alone after IPG depletion, while 10 required IPG replacement (6) or another advanced therapy (Levodopa-Carbidopa Intestinal Gel, 4) within the first year (27.4±25.1 days from IPG depletion)... Patients with LSPD and DBS with a longer duration of DBS therapy, prolonged stability of stimulation parameters without modifications, and a higher impact of fall risk seem to better tolerate the discontinuation of the stimulation, continuing acceptably with medical therapy and conservative treatments alone, while patients who still experience benefit from therapy on motor symptoms tend to require ongoing device-aided therapies within three months from IPG depletion. Table 1"

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Efficacy and Safety of IPX203 and Levodopa-Carbidopa Intestinal Gel (LCIG) Compared to Immediate-Release Carbidopa-Levodopa in Parkinson's Disease: A Systematic Review and Meta-Analysis (MDS Congress 2025) - "LCIG was efficacious in reducing off-time and was recommended for PD patients with severe motor fluctuations. For patients preferring noninvasive therapy, IPX203 can be a good oral alternative but did not significantly outperform IR CD-LD. Both drugs showed a comparable safety profile with low adverse effects."

Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

A case of Parkinson's Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations (MDS Congress 2025) - "Other medications, that were droxidopa 900mg and rotigotine 13.5mg, were not changed. Patients with PD sometimes experience long-term fluctuations possibly due to temperature change, stressful situations, and bad health condition other than PD, even when medication is not changed. In this patient, careful LCIG dose change by the family member might prevent long-term fluctuations. Fig."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

DIRECT PERCUTANEOUS ENDOSCOPIC JEJUNOSTOMY VERSUS PERCUTANEOUS ENDOSCOPIC GASTROSTOMY WITH JEJUNAL EXTENSION: QUALITY OF LIFE AND COMPLICATIONS (UEGW 2025) - "Introduction: Jejunal feeding and medication such as levodopa-carbidopa intestinal gel for Parkinson's disease can be administered via percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) and direct percutaneous endoscopic jejunostomy (D-PEJ)... In conclusion, D-PEJ is an interesting alternative for PEG-J. D-PEJ should at least be considered in patients with frequent problems with the jejunal extension of their PEG-J."

HEOR • CNS Disorders • Movement Disorders • Parkinson's Disease

SUBCUTANEOUS APOMORPHINE INFUSION EFFECTS ON OFF TIME AND MOTOR SYMPTOMS IN INDIVIDUALS WITH PARKINSON'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS (WCN 2025) - "Continuous subcutaneous Apomorphine infusion offers a less invasive alternative to device-aided therapies such as deep brain stimulation and Levodopa-Carbidopa intestinal gel. This systematic review supports the efficacy of Apomorphine infusion in reducing OFF time and improving motor symptoms in individuals with advanced PD. Apomorphine infusion represents a treatment option, particularly for patients ineligible for surgical interventions."

Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Development and Acceptability Testing of a Patient Decision Aid on Levodopa Intestinal Gel for Parkinson Disease. (PubMed, MDM Policy Pract) - "More research will be needed to evaluate the PDA's implementation and its effects on users. Deciding whether to opt for an advanced Parkinson's disease treatment such as levodopa-carbidopa intestinal gel can be challenging for many patients.A patient decision aid on levodopa-carbidopa intestinal gel for Parkinson's disease persons, caregivers, and health care professionals was developed to support a decision-making process.This article summarizes the steps used for its development and its acceptability testing."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Efficacy of levodopa/carbidopa intestinal gel infusion on neuropsychiatric fluctuations in parkinson's disease (EAN 2025) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series. (PubMed, Mov Disord Clin Pract) - "Switching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease (clinicaltrials.gov) - P=N/A | N=839 | Completed | Sponsor: AbbVie | N=152 ➔ 839

Enrollment change • CNS Disorders • Movement Disorders • Parkinson's Disease

Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson's disease. (PubMed, Clin Park Relat Disord) - "To achieve CDS, patients with advanced PD may require device-assisted therapies (DATs), including levodopa-carbidopa intestinal gel (LCIG), which have significantly improved swallowing function on some measures. This study provides preliminary evidence that CSCI-FF may partially improve swallowing function in patients with advanced PD. Further research with larger cohorts is warranted."

Journal • CNS Disorders • Gastrointestinal Disorder • Infectious Disease • Movement Disorders • Parkinson's Disease • Pneumonia • Respiratory Diseases

Levodopa-carbidopa intestinal gel for multiple system atrophy with motor fluctuations: a case series. (PubMed, Ther Adv Neurol Disord) - "However, long-term follow-up revealed a gradual decline in ADLs due to disease progression. These cases suggest that LCIG may be a valuable treatment option for selected MSA-P patients with preserved levodopa responsiveness."

Journal • CNS Disorders • Movement Disorders • Multiple System Atrophy • Parkinson's Disease

Levodopa-Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study. (PubMed, Mov Disord Clin Pract) - P=N/A | "LCIG led to reductions in dyskinesia severity, regardless of baseline dyskinesia burden. Dyskinesia duration improved in patients with high dyskinesia burden but not in those with low dyskinesia burden."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease • Sleep Disorder

Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease (clinicaltrials.gov) - P=N/A | N=152 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease

Long term follow-up of MSA patients on 24 hour continuous LCIG infusion: a case series. (PubMed, Parkinsonism Relat Disord) - No abstract available

Journal • CNS Disorders • Movement Disorders • Multiple System Atrophy